Bone Marrow Transplant Induction and Conditioning in One
Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT.
Actinium Pharmaceuticals' drug development pipeline features Iomab-B with positive pivotal Phase 3 results, Iomab-ACT, which is intended to be a conditioning regimen for cell and gene therapies and Actimab-A, which is being studied in combination with other regimens in AML to leverage its mutation-agnostic, resistant mechanism of action in collaboration under the NCI CRADA for late-stage development. Actinium is focused on continuing to expand its drug development pipeline of targeted radiotherapies for patients with blood cancers and solid tumors.
